Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norland's pDexa Bone Densitometer Cleared To Predict Fracture Risk

This article was originally published in The Gray Sheet

Executive Summary

Norland Medical Systems gained 510(k) clearance Feb. 9 to market a bone fracture risk assessment feature for its pDexa x-ray bone densitometry system.

You may also be interested in...



Sunlight To Pursue Omnisense Bone Sonometer Multi-Site Indications In U.S.

Sunlight Ultrasound Technologies plans to pursue FDA approval of multi-site indications for its Omnisense ultrasound bone sonometer following Jan. 20 premarket approval for assessing skeletal fragility along the distal radius (wrist) bone.

Novartis Emphasizes Message On Spinning Off Sandoz

Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel